GlassScriptPhysician profile
Steven D Feiner
NPI 1407895758
$2,231.31
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $354 · 2021: $794 · 2022: $211.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $412.60 | 2019-2022 | |
| Abbvie INC. | $397.68 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $390.76 | 2019-2022 | |
| Janssen Biotech, INC. | $214.33 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $100.10 | 2020-2022 | |
| Vivus LLC | $72.15 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $67.72 | 2021-2022 | |
| Daiichi Sankyo INC. | $63.74 | 2019-2021 | |
| Axonics, INC. | $62.62 | 2021 | |
| Pfizer INC. | $62.13 | 2020-2021 | |
| Amgen INC. | $55.59 | 2019 | |
| Celgene Corporation | $50.97 | 2021-2022 | |
| Medtronic, INC. | $41.47 | 2021 | |
| Gilead Sciences, INC. | $26.53 | 2019-2020 | |
| Amarin Pharma, INC. | $26.04 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $24.48 | 2019 | |
| Ucb, INC. | $22.72 | 2019-2020 | |
| Bausch Health US, LLC | $22.58 | 2019 | |
| Shionogi INC | $21.81 | 2019 | |
| Endo Pharmaceuticals INC. | $20.75 | 2019 | |
| Redhill Biopharma INC. | $18.50 | 2020 | |
| Fresenius USA Marketing, INC. | $17.82 | 2019 | |
| Shire North American Group INC | $13.41 | 2019 | |
| Braintree Laboratories, INC. | $12.42 | 2019 | |
| Sanofi Pasteur INC. | $12.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Feiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.